Latest News and Press Releases

OTTAWA, April 06, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to...

Bioanalytical methods developed and validated for its clinical trials. Tetra initiates study to quantify phytocannabinoid metabolites and precursors and minor phytocannabinoids in human plasma. ...

OTTAWA, March 30, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX-V: TBP) (OTCQB: TBPMF), announced today it has filed an amended and restated management’s...

OTTAWA, March 26, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced...

OTTAWA, March 23, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today would...

OTTAWA, March 06, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to...

OTTAWA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to...

CAUMZ targeting survival indications in advanced incurable cancer. Eligible for Fast Track designation and Accelerated Approval regulatory program.505(b)(2) NDA pathway provides significant cost...

QIXLEEF global market is expanded to include noncancer pain indications.Scientific approach to quality control of QIXLEEF validated by FDA.  OTTAWA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Tetra...

A first of its kind synthetic cannabinoid medication to manage eye pain in the veterinary setting Trial expected to be completed by April 30, 2020 OTTAWA, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Tetra...